Publications by authors named "Nathan Enas"

Claim this Profile
L
Leveraging historical data into oncology development programs: Two case studies of phase 2 Bayesian augmented control trial designs.
Claire L Smith, Zachary Thomas, Nathan Enas, Katharine Thorn, Michael Lahn

Pharm Stat· May 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Early change in tumour size predicts overall survival in patients with first-line metastatic breast cancer.
Sonya C Tate, Valerie Andre, Nathan Enas, Benjamin Ribba, Ivelina Gueorguieva

Eur J Cancer· October 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Models for change in tumour size, appearance of new lesions and survival probability in patients with advanced epithelial ovarian cancer.
Chiara Zecchin, Ivelina Gueorguieva, Nathan H Enas, Lena E Friberg

Br J Clin Pharmacol· September 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase 1/2 study of ocaratuzumab, an Fc-engineered humanized anti-CD20 monoclonal antibody, in low-affinity FcγRIIIa patients with previously treated follicular lymphoma.
Kristen N Ganjoo, Sven de Vos, Brad L Pohlman, Ian W Flinn, Andres Forero-Torres, Nathan H Enas

Leuk Lymphoma· January 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Use of historical control data for assessing treatment effects in clinical trials.
Kert Viele, Scott Berry, Beat Neuenschwander, Billy Amzal, Fang Chen, Nathan Enas

Pharm Stat· October 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Randomized, double-blind, phase II trial comparing gemcitabine-cisplatin plus the LTB4 antagonist LY293111 versus gemcitabine-cisplatin plus placebo in first-line non-small-cell lung cancer.
Pasi A Jänne, Luis Paz-Ares, Yun Oh, Corinna Eschbach, Vera Hirsh, Nathan Enas

J Thorac Oncol· January 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
In Vivo Measurements of Tumor Metabolism and Growth after Administration of Enzastaurin Using Small Animal FDG Positron Emission Tomography.
Karen E Pollok, Michael Lahn, Nathan Enas, Ann McNulty, Jeremy Graff

J Oncol· July 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Randomization by minimization for unbalanced treatment allocation.
Baoguang Han, Nathan H Enas, Damian McEntegart

Stat Med· November 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase I pharmacokinetic and pharmacodynamic study of the oral protein kinase C beta-inhibitor enzastaurin in combination with gemcitabine and cisplatin in patients with advanced cancer.
Jeany M Rademaker-Lakhai, Laurens V Beerepoot, Niven Mehra, Sandra A Radema, Rianne van Maanen, Nathan Enas

Clin Cancer Res· August 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase II study of enzastaurin, a protein kinase C beta inhibitor, in patients with relapsed or refractory diffuse large B-cell lymphoma.
Michael J Robertson, Brad S Kahl, Julie M Vose, Sven de Vos, Mary Laughlin, Nathan Enas

J Clin Oncol· May 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase I dose escalation and pharmacokinetic study of enzastaurin, an oral protein kinase C beta inhibitor, in patients with advanced cancer.
Michael A Carducci, Luna Musib, Merrill S Kies, Roberto Pili, Mylene Truong, Nathan Enas

J Clin Oncol· September 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Randomized phase II studies and their ethics.
Raymond P Abratt, William H H Reece, Nathan H Enas, Richard Stephens

J Clin Oncol· December 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase I trial of the cryptophycin analogue LY355703 administered as an intravenous infusion on a day 1 and 8 schedule every 21 days.
James P Stevenson, Weijing Sun, Maryann Gallagher, Robert Johnson, David Vaughn, Nathan Enas

Clin Cancer Res· August 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis